STOCK TITAN
  1. Home
  2. News
  3. ATHA

Athira Pharma Inc - ATHA STOCK NEWS

Welcome to our dedicated news page for Athira Pharma (Ticker: ATHA), a resource for investors and traders seeking the latest updates and insights on Athira Pharma.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Athira Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Athira Pharma's position in the market.

News
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
Rhea-AI Summary
Athira Pharma appoints Javier San Martin, M.D., as Chief Medical Officer, bringing over 25 years of drug development experience to lead the company's global development and commercialization strategies. Dr. San Martin will play a key role in advancing the pipeline of therapeutic candidates for neurodegenerative diseases, including Alzheimer's disease and ALS. His expertise in rare diseases and clinical development will strengthen Athira's position in the drug development landscape.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.57%
Tags
management
-
News
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Rhea-AI Summary
Athira Pharma, Inc. announces promising preclinical data on fosgonimeton for Alzheimer's disease treatment. Fosgonimeton shows neuroprotective effects, counteracts Aβ-induced toxicity, and enhances neuronal health. Key findings include improved neuronal survival, reduced tau hyperphosphorylation, enhanced activation of pro-survival effectors, and cognitive improvement in preclinical models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.85%
Tags
clinical trial
-
News
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
Rhea-AI Summary
Athira Pharma to present therapeutic potential of small molecules targeting neurotrophic HGF system for neurodegenerative disorders at AAN 2024 Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.81%
Tags
none
News
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
Rhea-AI Summary
Athira Pharma presents positive data on fosgonimeton at AD/PD 2024, supporting its potential in treating neurodegenerative diseases like Parkinson's and Alzheimer's. Encouraging safety and pro-cognitive measures from the SHAPE Phase 2 trial boost confidence in the ongoing LIFT-AD trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.73%
Tags
clinical trial
-
News
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
Rhea-AI Summary
Athira Pharma, Inc. completes enrollment in Phase 2/3 LIFT-AD clinical trial for potential Alzheimer's treatment, with topline data expected in 2024. Strong balance sheet supports innovative pipeline. ATH-1105 for ALS treatment on track for first-in-human studies in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
earnings
-
News
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
Rhea-AI Summary
Athira Pharma, Inc. (NASDAQ: ATHA) announced the publication of research demonstrating the neuroprotective and anti-inflammatory effects of ATH-1105 in preclinical models of amyotrophic lateral sclerosis (ALS). The small-molecule drug candidate showed significant benefits in cell culture and in vivo models of ALS, including protection of spinal motor neurons, preservation of neuromuscular junction integrity, reduction of inflammation, and extension of survival. The research findings support the potential of ATH-1105 as a new treatment option for ALS, with plans to advance into first-in-human studies in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.73%
Tags
none
News
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
Rhea-AI Summary
Athira Pharma, Inc. (NASDAQ: ATHA) completes Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer’s disease and expects topline data in second half of 2024. Plans to initiate first-in-human studies of ATH-1105 to treat amyotrophic lateral sclerosis in first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.45%
Tags
none
-
News
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Rhea-AI Summary
Athira Pharma, Inc. (NASDAQ: ATHA) completes enrollment in the Phase 2/3 LIFT-AD clinical trial of fosgonimeton for mild-to-moderate Alzheimer’s disease. Independent analysis supports trial continuation and potential clinically meaningful activity of fosgonimeton. The topline data is on track for the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.84%
Tags
clinical trial
-
News
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
Rhea-AI Summary
Athira Pharma, a late clinical-stage biopharmaceutical company (NASDAQ: ATHA), announced findings from the exploratory SHAPE Phase 2 clinical trial of fosgonimeton (ATH-1017) in patients with Parkinson’s disease dementia and dementia with Lewy Bodies. The 40 mg dose group showed positive effects in cognitive measures compared to placebo, with statistically significant differences in ADAS-Cog13, MMSE, and COWAT. The primary endpoint was not met, but all patients in the 40 mg group saw improvement in ADAS-Cog13, supporting the potential of targeting HGF system positive modulation for treating neurodegenerative diseases. The company is on track to complete enrollment in the ongoing Phase 2/3 LIFT-AD clinical trial of fosgonimeton in Alzheimer’s disease in early 2024 and report topline results in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.41%
Tags
clinical trial
News
Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
Rhea-AI Summary
Athira Pharma, Inc. (NASDAQ: ATHA) is a late clinical-stage biopharmaceutical company focusing on developing small molecules to restore neuronal health and slow neurodegeneration. The company announced its participation in the Sidoti December Small Cap Conference to highlight novel therapeutic candidates targeting the HGF neurotrophic system in late-stage clinical development for neurodegenerative diseases, including Alzheimer’s disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.43%
Tags
conferences
Stock ATHA logo
Athira Pharma Inc

Nasdaq:ATHA

ATHA Rankings

#4493 Ranked by Market Cap
#4750 Ranked by Stock Gains
N/A Ranked by Dividends

ATHA Stock Data

80.87M
26.94M
2.19%
62.85%
2.63%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Bothell

About ATHA

m3 biotechnology is an innovative therapeutics company that has a novel platform of disease-modifying regenerative small molecules, particularly relevant to neurodegenerative diseases. the lead compound modifies growth-factor systems, where the activation is expected to stop disease progression and even restore lost function. the company’s research has been funded by the alzheimer’s drug discovery foundation, washington’s life sciences discovery fund, w fund, wrf capital, dolby family ventures and other private investors. where current and emerging therapies are focused primarily on disease symptoms and improving the quality of life of patients suffering from disease, m3 differentiates itself from the competition by addressing the neurodegenerative process, providing a cost-effective solution and feasible delivery mechanism. our strategy is to leverage our patented and proprietary technologies to develop small molecule modulators with a primary focus on altering the course of alzheimer